<toc_element>
    <toc_label/>
    <toc_type>References</toc_type>
    <sec_element>
        <sec_header/>
        <subsec_element>
            <subsec_header/>
            <slide_intro>
                <ol>
                    <li>Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. 
                        <em>J Clin Oncol</em>. 2015;33:654-656.
                    </li>
                    <li>Cohen AT. Discoveries in thrombosis care for medical patients. 
                        <em>Semin Thromb Hemost</em>. 2002;28(suppl 3):13-17.
                    </li>
                    <li>ClinicalTrials.gov. Apixaban for the prevention of venous thromboembolism in cancer patients (AVERT). https://clinicaltrials.gov/ct2/show/NCT02048865. Accessed August 23, 2018.</li>
                    <li>Khorana AA, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: rationale and design of the CASSINI trial. 
                        <em>Thromb Haemost</em>. 2017;117:2135-2145.
                    </li>
                    <li>Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. 
                        <em>N Engl J Med.</em> 2018;378:615-624.
                    </li>
                    <li>Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). 
                        <em>J Clin Oncol</em>. 2018;36:2017-2023.
                    </li>
                    <li>Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. 
                        <em>N Engl J Med</em>. 2003;349:146-153.
                    </li>
                    <li>Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. 
                        <em>Res Pract Thromb Haemost</em>. 2017;1:14-22.
                    </li>
                    <li>Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. 
                        <em>Blood</em>. 2002;100:3484-3488.
                    </li>
                    <li>Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer associated venous thromboembolism. 
                        <em>Circulation</em> 2012; 126: 448-454.
                    </li>
                    <li>Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. 
                        <em>J Thromb Haemost</em>. 2018. [Epub ahead of print]
                    </li>
                    <li>Clinicaltrials.gov. Apixaban for the treatment of venous thromboembolism in patients with cancer (CARAVAGGIO) https://clinicaltrials.gov/ct2/show/NCT03045406. Accessed August 23, 2018.</li>
                </ol>
            </slide_intro>
        </subsec_element>
    </sec_element>
    <pg_footnotes/>
</toc_element>